We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Antipsychotic Properties of Des-Enkephalin-γ-Endorphin in Treatment of Schizophrenic Patients

Wim M. A. Verhoeven, MD; Jan M. van Ree, MD; Ans Heezius-van Bentum, MD; David de Wied, MD; Herman M. van Praag, MD
Arch Gen Psychiatry. 1982;39(6):648-654. doi:10.1001/archpsyc.1982.04290060010003.
Text Size: A A A
Published online


• Animal experiments have shown that the γ-endorphin fragment des-enkephalin-γ-endorphin (DEγE; β-lipotropin 66-77) is the shortest sequence with neuroleptic-like activity with potency comparable to des-tyrosine-γ-endorphin. We postulated that DEγE may be an endogenous peptide implicated in psychopathologic disease, particularly schizophrenia. To investigate the purported antipsychotic action of DEγE, 23 patients with different types of relapsing schizophrenia were treated with DEγE dissolved in saline or placebo. Neuroleptic medication was continued during the experimental period. In the first singleblind trial, two patients were treated with 1 mg of DEγE and two with 10 mg of DEγE intramuscularly (IM) daily for ten days. In the second double-blind placebo-controlled trial 13 patients were treated with 3 mg of DEγE IM daily for ten days and six received placebo. Of the 17 patients treated with DEγE, two did not respond, 11 had a slight to moderate effect, and four responded markedly. No side effects were observed. The response to DEγE appeared to be negatively correlated with the dosage of neuroleptic medication and the duration of the last psychotic episode. These results support the hypothesis that disturbances in γ-endorphin fragmentation might contribute to the pathogenesis of schizophrenic psychoses.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.